Management of Hyperglycemic Crises: DKA & HHS

 Hyperglycemic Crises: DKA & HHS

---

1. Overview of Hyperglycemic Crises

• DKA: A life-threatening emergency characterized by hyperglycemia (glucose >200 mg/dL), ketosis (β-Hydroxybutyrate >3.0 mmol/L), and metabolic acidosis (pH <7.3).

• HHS: Marked by severe hyperglycemia (glucose >600 mg/dL), hyperosmolality (>320 mOsm/kg), and absence of significant ketosis or acidosis.

---

2. Epidemiology and Pathophysiology

• Epidemiology:

• Increasing global incidence, particularly in adults under 45 years for DKA and older adults for HHS.

• Common triggers: infections (UTI, pneumonia), insulin omission, SGLT2 inhibitors, and physiological stress.

• COVID-19 impact: Higher rates of DKA in new-onset diabetes.

• Pathophysiology:

• DKA: Absolute insulin deficiency leads to lipolysis, free fatty acid release, ketogenesis, and acidosis.

• HHS: Relative insulin deficiency prevents ketogenesis but leads to severe hyperglycemia and dehydration.

---

3. Diagnostic Criteria

Criteria	DKA	HHS
Glucose (mg/dL)	>200	>600
Ketones	Positive (β-Hydroxybutyrate >3.0 mmol/L)	Negative or minimal (<3.0 mmol/L)
pH	<7.30	≥7.30
Bicarbonate (mmol/L)	<18	≥15
Osmolality (mOsm/kg)	<320	>320
Mental Status	Altered, ranging from alert to stupor	Confusion to coma

---

4. Treatment Strategies

A. Fluid Therapy

• DKA:

• Initial: 0.9% saline at 15-20 mL/kg/h.

• Adjust to hydration status and sodium levels. Add dextrose when glucose <250 mg/dL.

• HHS:

• Start with 0.9% saline. Transition to 0.45% saline if sodium is elevated.

• Add dextrose when glucose <300 mg/dL.

B. Insulin Therapy

• DKA:

• IV insulin infusion: Start at 0.1 units/kg/h.

• Reduce rate once glucose <200 mg/dL. Overlap IV insulin with subcutaneous insulin during transition.

• HHS:

• Initiate after fluids to avoid rapid osmolality shifts. Target glucose reduction of 50-70 mg/dL/h.

C. Electrolyte Management

• Potassium:

• Monitor closely. Replace if <5.0 mmol/L. Delay insulin if K+ <3.5 mmol/L.

• Bicarbonate:

• Consider only if pH <7.0. Avoid routine use.

• Phosphate:

• Replace only if <1.0 mmol/L with muscle weakness or respiratory compromise.

D. Monitoring

• Frequent monitoring of:

• Glucose: Every 1-2 hours.

• pH, ketones, and electrolytes: Every 2-4 hours.

• Mental status and urine output.

E. Treatment Timeline and Goals

Condition	Timeline	Goals
DKA	0-6 hours	Restore perfusion, glucose <300 mg/dL, pH >7.1, start insulin, potassium repletion.
	6-12 hours	Glucose <250 mg/dL, ketones <0.6 mmol/L, avoid osmolality shifts.
	12-24 hours	Normalize pH (>7.3), bicarbonate (>18 mmol/L), address triggers.
	24-48 hours	Stabilize glucose (<180 mg/dL), transition to subcutaneous insulin.
HHS	0-6 hours	Restore perfusion, glucose <350 mg/dL, start insulin after fluid replacement.
	6-12 hours	Gradual glucose reduction (target 50-70 mg/dL/h), avoid rapid shifts.
	12-24 hours	Normalize osmolality (<320 mOsm/kg), improve mental status.
	24-48 hours	Stabilize glucose (<180 mg/dL), maintain hydration, transition insulin.

---

5. Complications and Risk Mitigation

Complication	Cause	Prevention/Management
Hypoglycemia	Excess insulin or delayed dextrose	Add dextrose when glucose <250 mg/dL
Cerebral Edema	Rapid osmolality shifts	Avoid rapid correction of glucose
Hypokalemia	Insulin-driven potassium shifts	Replace potassium as needed
Thrombosis	Dehydration and hyperviscosity	Adequate hydration, consider prophylaxis

---

6. Criteria for Resolution

• DKA:

• Glucose <200 mg/dL, Ketone <0.6 mmol/L, pH >7.3, Bicarbonate >18 mmol/L.

• HHS:

• Glucose <250 mg/dL, Serum osmolality <300 mOsm/kg, Normal mental status.

---

7. Transition to Maintenance Insulin Therapy

Once DKA or HHS is resolved, transitioning to subcutaneous insulin therapy is essential to prevent recurrence and ensure stable glucose control. Key steps include:

1. Timing of Transition:

• Begin subcutaneous insulin 1-2 hours before discontinuing IV insulin to prevent hyperglycemia.

2. Insulin Regimen:

• Calculate Total Daily Dose (TDD): Use 0.5-0.6 units/kg for insulin-naïve patients. For people with risk factors for hypoglycemia, including kidney failure or frailty, a calculation using approximately 0.3 units/kg/day is recommended.

• Split TDD:

• 50% as basal insulin (e.g., glargine or detemir).

• 50% as bolus insulin divided across meals.

3. Special Considerations:

• Monitor closely for hypoglycemia, particularly in patients with renal impairment or low nutritional intake.

• Educate patients on insulin use, glucose monitoring, and recognizing signs of hypo- or hyperglycemia.

4. Follow-Up:

• Arrange outpatient follow-up within 1-2 weeks to assess glucose control and adjust the regimen as needed.

---

8. Learning Resources

• Key Guidelines:

• ADA Consensus Report on Hyperglycemic Crises (2024).

• European Association for the Study of Diabetes (EASD) recommendations.

• Recommended Reading:

• Textbooks on Critical Care Pharmacotherapy.

• Recent studies on SGLT2 inhibitors and DKA.

---

Appendix: Study Questions

1. What are the primary differences between DKA and HHS in terms of pathophysiology?

2. Describe the stepwise approach to treating severe DKA.

3. How does the use of SGLT2 inhibitors influence the risk of DKA?

---

Practice Multiple-Choice Questions

Questions

1. What is the primary difference in pathophysiology between DKA and HHS?
   a) Presence of significant ketosis in HHS
   b) Severe dehydration in DKA
   c) Significant ketosis in DKA
   d) Equal severity of acidosis in both conditions

2. Which of the following triggers is most commonly associated with DKA?
   a) Excessive carbohydrate intake
   b) Insulin omission
   c) Hyperthyroidism
   d) Hemorrhage

3. What is the recommended initial fluid therapy for a patient with HHS?
   a) Dextrose 5% in water
   b) 0.9% saline
   c) Lactated Ringer's solution
   d) 0.45% saline

4. When should subcutaneous insulin be initiated during the transition from IV insulin in DKA management?
   a) Immediately after stopping IV insulin
   b) 2-4 hours after stopping IV insulin
   c) 1-2 hours before stopping IV insulin
   d) Concurrently with stopping IV insulin

5. What is the target glucose reduction rate for patients with HHS during the first 6-12 hours?
   a) 50-70 mg/dL per hour
   b) 20-30 mg/dL per hour
   c) 100-150 mg/dL per hour
   d) No reduction during this period

6. Which electrolyte should be closely monitored and replaced during DKA management?
   a) Sodium
   b) Potassium
   c) Calcium
   d) Chloride

7. For a patient with severe DKA and a pH <7.0, what additional treatment may be considered?
   a) Phosphate replacement
   b) Sodium bicarbonate
   c) Magnesium sulfate
   d) Insulin bolus

8. What is the main cause of cerebral edema in the treatment of DKA?
   a) Rapid correction of glucose
   b) Hypernatremia
   c) Delayed fluid therapy
   d) Excessive insulin administration

9. Which criterion is essential to confirm resolution of DKA?
   a) Normal osmolality (<300 mOsm/kg)
   b) pH >7.1
   c) Bicarbonate >18 mmol/L
   d) Glucose <200 mg/dL

10. What is the recommended Total Daily Dose (TDD) of insulin for insulin-naïve patients transitioning to maintenance therapy?
    a) 0.3 units/kg/day
    b) 0.5-0.6 units/kg/day
    c) 1.0 units/kg/day
    d) 0.8 units/kg/day

---

Answers and Explanations

1. c) Significant ketosis in DKA

• DKA involves ketosis and metabolic acidosis, while HHS does not.

2. b) Insulin omission

• Common triggers for DKA include infection and missing insulin doses.

3. b) 0.9% saline

• Initial fluid therapy for both DKA and HHS typically begins with isotonic saline.

4. c) 1-2 hours before stopping IV insulin

• To avoid rebound hyperglycemia, subcutaneous insulin should overlap with IV insulin.

5. a) 50-70 mg/dL per hour

• This gradual reduction helps prevent complications like cerebral edema.

6. b) Potassium

• Hypokalemia is a common issue in DKA management due to insulin and fluid therapy.

7. b) Sodium bicarbonate

• Considered only if pH is <7.0, as it may carry risks of complications.

8. a) Rapid correction of glucose

• Rapid osmolality changes from glucose correction can cause cerebral edema.

9. d) Glucose <200 mg/dL

• Resolution criteria also include pH >7.3 and bicarbonate >18 mmol/L.

10. b) 0.5-0.6 units/kg/day

• This is the standard calculation for insulin-naïve patients; adjust for risk factors.

---

Management and Medication-Focused Practice Questions

Questions

1. Which insulin dosing strategy is preferred for IV insulin therapy in managing DKA?
   a) Bolus insulin every 6 hours
   b) Subcutaneous insulin every 12 hours
   c) Continuous infusion at 0.1 units/kg/hour
   d) Intramuscular insulin every 4 hours

2. What is the initial fluid therapy for a patient with DKA who presents with normal serum sodium levels?
   a) 0.9% saline at 15-20 mL/kg/hour
   b) 0.45% saline at 10 mL/kg/hour
   c) Lactated Ringer’s solution at 5 mL/kg/hour
   d) Dextrose 5% in water

3. When should potassium supplementation begin in the treatment of DKA?
   a) Only when serum potassium is <3.5 mmol/L
   b) When serum potassium is <5.0 mmol/L
   c) Only after pH normalization
   d) Potassium supplementation is not required in DKA

4. Which of the following medications should be avoided or used with caution in patients at risk of HHS?
   a) Metformin
   b) Sulfonylureas
   c) SGLT2 inhibitors
   d) All of the above

5. What is the primary goal of insulin therapy in the initial 6 hours of DKA management?
   a) Reduce serum glucose by 50-70 mg/dL per hour
   b) Normalize serum pH to >7.35
   c) Eliminate serum ketones completely
   d) Normalize serum osmolality

6. For a patient with severe DKA (pH <7.0), what additional treatment should be considered?
   a) Sodium bicarbonate
   b) Magnesium sulfate
   c) Calcium gluconate
   d) Albumin infusion

7. What is the recommended glucose level target for transitioning to dextrose-containing fluids during DKA treatment?
   a) <300 mg/dL
   b) <250 mg/dL
   c) <200 mg/dL
   d) <180 mg/dL

8. During HHS management, insulin infusion should be initiated:
   a) Immediately upon diagnosis
   b) After fluid replacement has started
   c) When serum glucose is <250 mg/dL
   d) Concurrently with bicarbonate administration

9. Which electrolyte imbalance is most likely to occur during DKA treatment with insulin therapy?
   a) Hypernatremia
   b) Hypokalemia
   c) Hypocalcemia
   d) Hyperphosphatemia

10. What is the recommended Total Daily Dose (TDD) of insulin for a frail elderly patient transitioning to maintenance therapy?
    a) 0.3 units/kg/day
    b) 0.5-0.6 units/kg/day
    c) 0.8 units/kg/day
    d) 1.0 units/kg/day

---

Answers and Explanations

1. c) Continuous infusion at 0.1 units/kg/hour

• Continuous infusion allows precise control of glucose and ketone levels during DKA treatment.

2. a) 0.9% saline at 15-20 mL/kg/hour

• Isotonic saline is preferred to restore intravascular volume.

3. b) When serum potassium is <5.0 mmol/L

• Potassium supplementation is needed to prevent hypokalemia due to insulin therapy.

4. d) All of the above

• Metformin, sulfonylureas, and SGLT2 inhibitors all have risks in hyperglycemic crises.

5. a) Reduce serum glucose by 50-70 mg/dL per hour

• Gradual glucose reduction minimizes the risk of cerebral edema.

6. a) Sodium bicarbonate

• Sodium bicarbonate may be considered if pH <7.0, though it should be used cautiously.

7. b) <250 mg/dL

• Adding dextrose prevents hypoglycemia when glucose reaches this level.

8. b) After fluid replacement has started

• Insulin therapy without adequate fluid resuscitation may worsen dehydration.

9. b) Hypokalemia

• Insulin drives potassium into cells, leading to a drop in serum levels.

10. a) 0.3 units/kg/day

• A lower insulin dose is recommended for frail patients to reduce hypoglycemia risk.

---